×
Please click
here
if you are not redirected within a few seconds.
All
News
Shopping
Images
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Precigen, Inc.'s (NASDAQ:PGEN) Path To Profitability
Simply Wall Street
With the business potentially at an important milestone, we thought we'd take a closer look at Precigen, Inc.'s...
3 days ago
Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd ...
Yahoo Finance
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve...
5 days ago
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse ...
PR Newswire
PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell...
3 weeks ago
Precigen (PGEN) Scheduled to Post Quarterly Earnings on Tuesday
Defense World
Precigen (NASDAQ:PGEN – Get Free Report) will be posting its quarterly earnings results after the market closes on Tuesday, May 14th.
2 days ago
Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day ...
PR Newswire
Precigen, RRP Awareness Day, Recurrent Respiratory Papillomatosis Awareness Day, RRP Awareness Day Giving Voice to Inspire Change, and Advancing...
1 month ago
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse ...
PR Newswire
Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of...
2 months ago
Precigen, Inc. (NASDAQ:PGEN): When Will It Breakeven?
Yahoo Finance
Consensus from 4 of the American Biotechs analysts is that Precigen is on the verge of breakeven. They anticipate the company to incur a final...
2 months ago
Precigen Reports Full Year 2023 Financial Results and Business Updates
PR Newswire
Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a...
1 month ago
Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate
Yahoo Movies Canada
Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study.
5 days ago
Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference
PR Newswire
Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an...
4 months ago